Brief: GT Biopharma Demonstrates Novel B7-H3 Targeting Dual Camelid Nanobody BiKE and GTB-5550 Induce NK Cell Activation Against Broad Spectrum of Tumors at ESMO IO Congress 2021

GT Biopharma

08/12/2021 12:32

Dec 8 (Reuters) - GT Biopharma Inc  GTBP.O :
    * GT BIOPHARMA DEMONSTRATES NOVEL B7-H3 TARGETING DUAL
CAMELID
NANOBODY BIKE AND GTB-5550 INDUCE NK CELL ACTIVATION AGAINST
BROAD SPECTRUM OF TUMORS AT ESMO IO CONGRESS 2021
    * GT BIOPHARMA INC - GTB-5550, WHICH HARBORS WILD-TYPE
IL-15, AND
BIKE DISPLAY BROAD ACTIVITY AGAINST B7-H3-EXPRESSING TUMORS
    * GT BIOPHARMA INC - COMPARED TO MONOMERIC IL-15, GTB-5550
SHOWS
CD16-DEPENDENT METABOLIC ACTIVATION OF NK CELLS

Source text for Eikon:  ID:nPn7rHRLza 
Further company coverage:  GTBP.O 

 ((Reuters.Briefs@thomsonreuters.com;;))